AbCellera Biologics ABCL

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.02 (-0.84%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of AbCellera Biologics (ABCL)
    AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $2.33

    • Market Cap

      $694.31 Million

    • Price-Earnings Ratio

      -3.82

    • Total Outstanding Shares

      297.99 Million Shares

    • Total Employees

      596

    • Dividend

      No dividend

    • IPO Date

      December 11, 2020

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      2215 yukon street, Vancouver, A1, V5Y 0A1

    • Homepage

      https://www.abcellera.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow$-45.78 Million
    Net Cash Flow From Operating Activities$-120.17 Million
    Exchange Gains/Losses$611,000
    Net Cash Flow From Financing Activities$12.39 Million
    Net Cash Flow From Operating Activities, Continuing$-120.17 Million
    Net Cash Flow From Investing Activities, Continuing$61.38 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Income Tax Expense/Benefit$-26.37 Million
    Diluted Earnings Per Share$-0.61
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Basic Earnings Per Share$-0.61
    Other Operating Expenses$146.83 Million
    Net Income/Loss Attributable To Parent$-175.80 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-175.57 Million
    Other Comprehensive Income/Loss$228,000
    Comprehensive Income/Loss$-175.57 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Assets$1.39 Billion
    Noncurrent Assets$649.95 Million
    Other Current Liabilities$73.58 Million
    Equity$1.08 Billion
    Liabilities$314.73 Million
    Intangible Assets$52.58 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ABCL from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.